{"analyses":[{"ciLowerLimit":"-11.608","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"21.835","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"8.532","estimateComment":"The treatment can be considered beneficial if the mean difference (treatment - control) slope is negative","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.55","paramType":"Slope","paramValue":"5.113","statisticalComment":"The treatment effect was determined by testing the significance of the group by time interaction in GEE using a one degree-of-freedom (df) test.","statisticalMethod":"Generalized Estimating Equation (GEE)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.3731","value":"85.6301"},{"groupId":"OG001","spread":"22.243","value":"115.7222"}]}],"title":"BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.7877","value":"90.7536"},{"groupId":"OG001","spread":"23.736","value":"128.9565"}]}],"title":"6m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.38","value":"87.7167"},{"groupId":"OG001","spread":"26.823","value":"115.6364"}]}],"title":"12m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.7275","value":"99.4912"},{"groupId":"OG001","spread":"18.5618","value":"93.2105"}]}],"title":"18m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.2521","value":"101.8333"},{"groupId":"OG001","spread":"26.6515","value":"107.8490"}]}],"title":"24m"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"N-terminal pro b-type natriuretic peptide- a biomarker for heart failure (in pg/ml). The mean is reported by arm at each timepoint with corresponding standard errors.","dispersionType":"Standard Error","groups":[{"description":"Patients received Carvedilol PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG000","title":"Arm I (Carvedilol)"},{"description":"Patients received Placebo PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG001","title":"Arm II (Placebo)"}],"paramType":"MEAN","populationDescription":"We excluded 31 participants who did not have a second time point assessment of echocardiography, resulting in 151 analyzable participants.","reportingStatus":"POSTED","timeFrame":"Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation","title":"Average Cardiac N-terminal Pro B-type Natriuretic Peptide","type":"SECONDARY","unitOfMeasure":"pg/mL"}